Modulation of metabolic functions through Cas13d-mediated gene knockdown in liver

References

[1] Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, Tang J, Liu Q, Higbee J, Xia Z(2009) A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 106:9820–9825

[2] Freije CA, Myhrvold C, Boehm CK, Lin AE, Welch NL, Carter A, Metsky HC, Luo CY, Abudayyeh OO, Gootenberg JS (2019) Programmable inhibition and detection of RNA viruses using Cas13. Mol Cell 76(826–837):e811

[3] Haeusler RA, Hartil K, Vaitheesvaran B, Arrieta-Cruz I, Knight CM, Cook JR, Kammoun HL, Febbraio MA, Gutierrez-Juarez R, Kurland IJ (2014) Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nat Commun 5:5190

[4] Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21:635–637

[5] Konermann S, Lotfy P, Brideau NJ, Oki J, Shokhirev MN, Hsu PD (2018) Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell 173(665–676):e614

[6] Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK (2012) The PCSK9 decade. J Lipid Res 53:2515–2524

[7] Li P, Ruan X, Yang L, Kiesewetter K, Zhao Y, Luo H, Chen Y, Gucek M, Zhu J, Cao H (2015) A liver-enriched long non-coding RNA, lncLSTR, regulates systemic lipid metabolism in mice. Cell Metab 21:455–467

[8] Moller DE (2012) Metabolic disease drug discovery- “hitting the target” is easier said than done. Cell Metab 15:19–24

[9] Pineda M, Lear A, Collins JP, Kiani S (2019) Safe CRISPR: challenges and possible solutions. Trends Biotechnol 37:389–401

[10] Price AA, Sampson TR, Ratner HK, Grakoui A, Weiss DS (2015) Cas9-mediated targeting of viral RNA in eukaryotic cells. Proc Natl Acad Sci USA 112:6164–6169

[11] Rossidis AC, Stratigis JD, Chadwick AC, Hartman HA, Ahn NJ, Li H, Singh K, Coons BE, Li L, Lv W (2018) In utero CRISPRmediated therapeutic editing of metabolic genes. Nat Med 24:1513–1518

[12] Steinberg D, Witztum JL (2009) Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci USA 106:9546–9547

[13] Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim YJ, Sherwin R, Devaskar S, Lesche R, Magnuson MA (2004) Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci USA 101:2082–2087

[14] Yan WX, Chong S, Zhang H, Makarova KS, Koonin EV, Cheng DR, Scott DA (2018) Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein. Mol Cell 70(327–339):e325

[15] Zhou C, Hu X, Tang C, Liu W, Wang S, Zhou Y, Zhao Q, Bo Q, Shi L, Sun X (2020) CasRx-mediated RNA targeting prevents choroidal neovascularization in a mouse model of age-related macular degeneration. Natl Sci Rev.

RIGHTS & PERMISSIONS

The Author(s) 2020